MA39857A - Promédicaments à base de succinate destinés à être utilisés dans le traitement de l'acidose lactique ou d'effets secondaires induits par un médicament dus à une déficience liée au complexe i de la phosphorylation oxydative mitochondriale - Google Patents

Promédicaments à base de succinate destinés à être utilisés dans le traitement de l'acidose lactique ou d'effets secondaires induits par un médicament dus à une déficience liée au complexe i de la phosphorylation oxydative mitochondriale

Info

Publication number
MA39857A
MA39857A MA039857A MA39857A MA39857A MA 39857 A MA39857 A MA 39857A MA 039857 A MA039857 A MA 039857A MA 39857 A MA39857 A MA 39857A MA 39857 A MA39857 A MA 39857A
Authority
MA
Morocco
Prior art keywords
treatment
drug
complex
effects due
lactic acidosis
Prior art date
Application number
MA039857A
Other languages
English (en)
Inventor
Karl Henrik Johannes Ehinger
Eskil Elmér
Magnus Joakim Hansson
Steven Moss
Sarah Piel
Original Assignee
Neurovive Pharmaceutical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurovive Pharmaceutical Ab filed Critical Neurovive Pharmaceutical Ab
Publication of MA39857A publication Critical patent/MA39857A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne un promédicament à base de succinate destiné à être utilisé dans le traitement ou la prévention de l'acidose lactique.
MA039857A 2014-04-08 2015-04-08 Promédicaments à base de succinate destinés à être utilisés dans le traitement de l'acidose lactique ou d'effets secondaires induits par un médicament dus à une déficience liée au complexe i de la phosphorylation oxydative mitochondriale MA39857A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470190 2014-04-08
DKPA201470185 2014-04-08
DKPA201470187 2014-04-08

Publications (1)

Publication Number Publication Date
MA39857A true MA39857A (fr) 2017-02-15

Family

ID=52988028

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039857A MA39857A (fr) 2014-04-08 2015-04-08 Promédicaments à base de succinate destinés à être utilisés dans le traitement de l'acidose lactique ou d'effets secondaires induits par un médicament dus à une déficience liée au complexe i de la phosphorylation oxydative mitochondriale

Country Status (14)

Country Link
US (1) US10307389B2 (fr)
EP (1) EP3129058A1 (fr)
JP (1) JP2017510603A (fr)
KR (1) KR20160135365A (fr)
CN (1) CN106255509A (fr)
AU (1) AU2015243353A1 (fr)
CA (1) CA2944575A1 (fr)
EA (1) EA201692020A1 (fr)
IL (1) IL247958A0 (fr)
MA (1) MA39857A (fr)
MX (1) MX2016012751A (fr)
SG (1) SG11201607908QA (fr)
WO (1) WO2015155238A1 (fr)
ZA (1) ZA201606611B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11147789B2 (en) 2014-04-08 2021-10-19 Abliva Ab Cell-permeable succinate compounds
WO2017060400A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des maladies liées à des dysfonctions mitochondriales
WO2017060422A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des troubles mitochondriaux
WO2017060418A1 (fr) * 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Métabolites protégés à base d'acide carboxylique pour le traitement des maladies liées aux mitochondries
US11565998B2 (en) 2019-06-19 2023-01-31 Abliva Ab Succinate prodrug, compositions containing the succinate prodrug and uses thereof
CN112479913A (zh) * 2020-11-19 2021-03-12 安徽修一制药有限公司 一种n,n-二乙基氯代乙酰胺的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0583480A4 (fr) * 1992-02-07 1994-03-18 Tsumura & Co Agent d'attenuation des effets secondaires.
GB9612331D0 (en) * 1996-06-13 1996-08-14 Leo Pharm Prod Ltd Chemical compounds
AUPR059400A0 (en) * 2000-10-06 2000-11-02 Bar-Ilan University Formaldehyde-releasing prodrugs
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
KR100791844B1 (ko) * 2006-06-30 2008-01-07 주식회사유한양행 메트포르민 또는 그의 염을 함유하는 서방성 제제 및 그의제조방법
KR101069502B1 (ko) * 2006-10-31 2011-09-30 (주)아모레퍼시픽 비만 및 당뇨병 개선용 경구용 조성물
AU2008230861A1 (en) 2007-03-26 2008-10-02 Salutria Pharmaceuticals, Llc Methods and compositions of derivatives of probucol for the treatment of diabetes
IT1406068B1 (it) * 2010-07-22 2014-02-06 Medestea Int Spa Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego
JP2014024772A (ja) 2012-07-25 2014-02-06 Univ Of Tokyo ミトコンドリアのａｔｐ産生能昂進剤
ES2661009T3 (es) * 2012-10-05 2018-03-27 Neurovive Pharmaceutical Ab Succinatos protegidos para mejorar la producción de ATP mitocondrial
WO2015155230A1 (fr) 2014-04-08 2015-10-15 Neurovive Pharmaceutical Ab Promédicaments d'acide succinique pour augmenter la production d'atp
US11147789B2 (en) 2014-04-08 2021-10-19 Abliva Ab Cell-permeable succinate compounds

Also Published As

Publication number Publication date
JP2017510603A (ja) 2017-04-13
AU2015243353A1 (en) 2016-10-13
MX2016012751A (es) 2016-12-12
US20170100359A1 (en) 2017-04-13
WO2015155238A1 (fr) 2015-10-15
KR20160135365A (ko) 2016-11-25
EA201692020A1 (ru) 2017-02-28
US10307389B2 (en) 2019-06-04
ZA201606611B (en) 2018-05-30
CA2944575A1 (fr) 2015-10-15
CN106255509A (zh) 2016-12-21
EP3129058A1 (fr) 2017-02-15
IL247958A0 (en) 2016-11-30
SG11201607908QA (en) 2016-10-28

Similar Documents

Publication Publication Date Title
HK1247922A1 (zh) 用於治療癌症的吲哚胺2，3-雙加氧酶抑制劑
EP3458053A4 (fr) Utilisation du riluzole, de promédicaments du riluzole ou d'analogues du riluzole avec des immunothérapies pour traiter les cancers
IL272724B (en) Gemcitabine drug inhibitors
MA39857A (fr) Promédicaments à base de succinate destinés à être utilisés dans le traitement de l'acidose lactique ou d'effets secondaires induits par un médicament dus à une déficience liée au complexe i de la phosphorylation oxydative mitochondriale
MX2017000363A (es) Inhibicion de la via de notch.
HK1244023A1 (zh) 水溶性超分子複合物
IL266012A (en) Combination therapy for c3 inhibition
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
IL247267A0 (en) Methods for the treatment of vascular invasive cancers
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
EP3226869A4 (fr) Promédicament inhibiteur de kinase pour le traitement du cancer
MX2017001490A (es) Combinaciones de farmacos para tratar mieloma multiple.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
GB201612872D0 (en) Prodrug compounds
IL252493B (en) Compounds for use in the prevention or treatment of cancer
MX2016014255A (es) Producto ceramico refractario.
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
MX2017008655A (es) Derivados de jasmonato y composiciones de los mismos.
BR112016019395A2 (pt) composição
PH12017501063A1 (en) Compounds for the treatment of cancer
GB2546703A (en) Compounds
TR201401768A2 (tr) Miyasteninin tedavisine yönelik bir kompozisyon.
TR201401730A2 (tr) Artroz'un semptomatik tedavisine yönelik bir kompozisyon.
AU2014126V (en) WA 2 Malus domestica